CSI Market
Sign In | Register

Bionano Genomics Inc (BNGO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BNGO Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Bionano Genomics Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-15.73
Depreciation & amortization4.61
Amortization of Other Assets0.00
Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.03
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.03
Share-based Compensation1.64
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Noncash Interest Expense-
Long Term Debt Prepayment Fees-
Finance Lease Right Of Use Asset Amortization0.05
Gain Loss On Extinguishment Of Debt Cash Expense-
Cost Of Leased Equipment Sold To Customer0.05
Fair Value Option Liability And Notes Payable Changes In Fair Value Gain Loss0.17
Non Cash Lease Expense-
Impairment Of Developed Technology-
Impairment Of Trade Names Customer Relationships And Other Long Lived Assets-
Non Cash Lease Expense Income0.12
Operating Lease Impairment Loss-
Income taxes0.00
Realized Investment Gains (Losses), Total0.00
Increase (Decrease) in Accounts Receivable-0.83
Increase (Decrease) in Accounts Payable-1.03
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-1.97
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.31
Other Working Capital-0.59
Other Noncash Income (Expense)0.00
Other net0.30
Payments for (Proceeds from) Other Operating Activities3.53
Discontinued operations0.00
Net Cash flow from Operating Activities-10.39
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities99.27
Payments to Acquire Available-for-sale Securities, Debt-80.13
Real Estate Investments0.00
Payments For Initial Costs On Leases-
Payments For Property And Equipment-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.04
Discontinued operations0.00
Net Cash Flow from Investing Activities19.14
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-10.27
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.25
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.02
Employee Stock Purchase Plan Compensation Expense-
Proceeds From P P P Loan-
Proceeds From Payroll Protection Program Loan-
Finance Lease Principal Payments-0.02
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations4.51
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-9.04
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-10.39
Total Cash Flow-0.28
4 historic quarters locked

Sign in to unlock the full Bionano Genomics Inc cash flow history.

Sign In Create Free Account

About Bionano Genomics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001411690-26-000044

Figures are derived from filed reports and may be restated. Historical data is subject to revision.